Sonnet Biotherapeutics Holdings Inc SONN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
1.83quote price arrow up+0.07 (+3.98%)
Volume
6,851
52 week range
1.08 - 26.40
Loading...
  • Open1.82
  • Day High1.82
  • Day Low1.75
  • Prev Close1.76
  • 52 Week High26.40
  • 52 Week High Date06/16/23
  • 52 Week Low1.08
  • 52 Week Low Date10/26/23

Key Stats

  • Market Cap5.617M
  • Shares Out3.07M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta0.60
  • YTD % Change4.05

KEY STATS

  • Open1.82
  • Day High1.82
  • Day Low1.75
  • Prev Close1.76
  • 52 Week High26.40
  • 52 Week High Date06/16/23
  • 52 Week Low1.08
  • 52 Week Low Date10/26/23
  • Market Cap5.617M
  • Shares Out3.07M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta0.60
  • YTD % Change4.05

RATIOS/PROFITABILITY

  • EPS (TTM)-12.91
  • P/E (TTM)-0.14
  • Fwd P/E (NTM)-2.79
  • EBITDA (TTM)-14.446M
  • ROE (TTM)-1,080.24%
  • Revenue (TTM)129,189.998
  • Gross Margin (TTM)4.53%
  • Net Margin (TTM)-11,192.09%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sonnet Biotherapeutics Holdings Inc

 

Profile

MORE
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010...
Pankaj Mohan Ph.D.
Chairman of the Board, President, Chief Executive Officer
John Cross
Chief Financial Officer
Address
100 Overlook Center, Suite 102
Princeton, NJ
08540
United States

Top Peers

SYMBOLLASTCHG%CHG
ATXI
Avenue Therapeutics Inc
4.15-0.25-5.68%
PCSA
Processa Pharmaceuticals Inc
2.13-0.35-14.11%
HOTH
Hoth Therapeutics Inc
1.20-0.01-0.83%
BPTH
Bio Path Holdings Inc
2.81+0.05+1.81%
OGEN
Oragenics Inc
1.38+0.17+14.05%